Dr. Konstantinos Tzelepis

The Tzelepis group (Milner Therapeutics Insitute and Wellcome Sanger Institute), led by Dr Konstantinos Tzelepis, focus on the discovery of novel therapeutic targets and the bench-toclinic transition of new treatments for aggressive malignancies including acute myeloid leukaemia (AML). Their recent work has led to the development of sophisticated CRISPR screening platforms which formed the basis for follow-up studies that identified the role of several new cancer vulnerabilities including the RNA methyltransferase METTL3 and the splicing kinase SRPK1. Now, the Tzelepis group is investigating how the structures and modifications of RNA regulate disease initiation and progression.

Dr Konstantinos Tzelepis

Further Information:

Team Members

Konstantinos Tzelepis (Principal Investigator)

Eliza Yankova (Postdoctoral Fellow)

Maria Eleftheriou (Postdoctoral Fellow)


  1. Yankova, Blackaby et al. Small molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 2021
  2. Orellana et al. METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation. Molecular Cell 2021
  3. Mikutis et al. meCLICK-Seq – a substrate-hijacking and RNA degradation strategy for the study of RNA methylation. ACS Central Science 2020